The majority of AML-DC reports focus on measuring circulating pDCs and cDCs (23, 56, 57)support the idea that FLT3-ITD+ AML patients have increased DC frequency in the peripheral blood. This evidence concerns the gene FLT3 and acute myeloid leukemia.